Showing 2631-2640 of 4063 results for "".
- Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinitehttps://modernod.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in p
- ARVO Women’s Leadership Development Program Welcomes Class of 2021https://modernod.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/The Association for Research in Vision and Ophthalmology (ARVO) recognized the 2021 class of its Women’s Leadership Development Program (WLDP). The program, provided through the support of Aerie Pharmaceuticals, is an interactive, year-long learning experience focused on leadership skill developm
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2021 Online Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-2021-online-conference/2479453/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 2021 Online Conference at www.nora2021.com. The conference will be available live online from Thursday, October 14 to Saturday, October 16, with select presenta
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In
- Glaukos Comments on the CMS 2022 Proposed Physician Fee Schedulehttps://modernod.com/news/glaukos-comments-on-the-cms-2022-proposed-physician-fee-schedule/2479412/Glaukos commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule. The Proposed Rule was released on July 13, 2021, and updates payment policies, payment rates and other provisions for services furnished un
- Surface Ophthalmics Announces $25 Million Private Round of Fundraisinghttps://modernod.com/news/surface-ophthalmics-announces-25-million-private-round-of-fundraising/2479393/Surface Ophthalmics announced it has secured gross proceeds of approximately $25 million in a private placement of preferred stock, at a purchase price of $4.50 per share. Investors in this round of financing included both new and existing investors made up of institutional, healthcare-focused, a
- Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRShttps://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an i
- Bausch + Lomb to Present 14 Scientific Posters Featuring New Analyses Involving its Surgical Technologies at ASCRS 2021https://modernod.com/news/bausch-lomb-to-present-14-scientific-posters-featuring-new-analyses-involving-its-surgical-technologies-at-ascrs-2021/2479382/Bausch + Lomb announced the presentation of 14 scientific posters involving the company’s ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place from July 23-27, 2021, in Las Vegas. “We are always pleased to
- Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RPhttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-phase-2b-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-rp/2479381/Nanoscope Therapeutics announced that the first patient had been dosed in its phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigme
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<